120077-67-0Relevant articles and documents
HETEROCYCLIC COMPOUND
-
Paragraph 0485, (2017/08/01)
The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.
COMPOUNDS
-
Page/Page column 37, (2012/06/01)
The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.
INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS
-
Page/Page column 44-45, (2008/12/06)
The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) processes for their preparation, pharmaceutical compositions containing them and their use in the treatment